Conversion surgery for stage IV gastric cancer: a multicenter retrospective study

[1]  Y. Kodera,et al.  International Retrospective Cohort Study of Conversion Therapy for Stage IV Gastric Cancer 1 (CONVO‐GC‐1) , 2021, Annals of gastroenterological surgery.

[2]  C. Gutschow,et al.  Gastric cancer with positive peritoneal cytology: survival benefit after induction chemotherapy and conversion to negative peritoneal cytology , 2021, World Journal of Surgical Oncology.

[3]  H. Katai,et al.  Impact of preoperative chemotherapy as initial treatment for advanced gastric cancer with peritoneal metastasis limited to positive peritoneal lavage cytology (CY1) or localized peritoneal metastasis (P1a): a multi-institutional retrospective study , 2020, Gastric Cancer.

[4]  S. Park,et al.  S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial. , 2020, The Lancet. Oncology.

[5]  Yun Wang,et al.  Surgical Outcome and Long-Term Survival of Conversion Surgery for Advanced Gastric Cancer , 2020, Annals of Surgical Oncology.

[6]  S. Natsugoe,et al.  Clinical Significance of Conversion Surgery for Gastric Cancer with Peritoneal Dissemination: A Retrospective Study , 2020, Oncology.

[7]  S. Ida,et al.  Conversion therapy for peritoneal lavage cytology-positive type 4 and large type 3 gastric cancer patients selected as candidates for R0 resection by diagnostic staging laparoscopy , 2019, Gastric Cancer.

[8]  T. Yoshikawa,et al.  Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial. , 2019, The lancet. Gastroenterology & hepatology.

[9]  G. Tiberio,et al.  Conversion gastrectomy for stage IV unresectable gastric cancer: a GIRCG retrospective cohort study , 2019, Gastric Cancer.

[10]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[11]  Kazuhiro Yoshida,et al.  International retrospective cohort study of conversion therapy for stage IV gastric cancer 1 (CONVO-GC-1). , 2018 .

[12]  A. Gardini,et al.  Conversion surgery for gastric cancer: A cohort study from a western center. , 2018, International journal of surgery.

[13]  S. Barni,et al.  Tumor regression grade and survival after neoadjuvant treatment in gastro-esophageal cancer: A meta-analysis of 17 published studies. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[14]  Kazuhiro Yoshida,et al.  The long-term survival of stage IV gastric cancer patients with conversion therapy , 2017, Gastric Cancer.

[15]  Japanese Gastric Cancer Association.  Japanese gastric cancer treatment guidelines 2014 (ver. 4) , 2016, Gastric Cancer.

[16]  Y. Kodera,et al.  Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification , 2015, Gastric Cancer.

[17]  J. Kinoshita,et al.  Efficacy of conversion gastrectomy following docetaxel, cisplatin, and S-1 therapy in potentially resectable stage IV gastric cancer. , 2015, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[18]  A. Nashimoto,et al.  The clinical significance of potentially curative resection for gastric cancer following the clearance of free cancer cells in the peritoneal cavity by induction chemotherapy , 2015, Surgery Today.

[19]  H. Kuwano,et al.  Prognostic Role of Conversion Surgery for Unresectable Gastric Cancer , 2015, Annals of Surgical Oncology.

[20]  K. Hatakeyama,et al.  Gastrectomy as a secondary surgery for stage IV gastric cancer patients who underwent S-1-based chemotherapy: a multi-institute retrospective study , 2012, Gastric Cancer.

[21]  Y. Kodera,et al.  Long-term follow up of patients who were positive for peritoneal lavage cytology: final report from the CCOG0301 study , 2012, Gastric Cancer.

[22]  H. Ohdan,et al.  Preliminary trial of adjuvant surgery for advanced gastric cancer. , 2010, Oncology letters.

[23]  Tae Won Kim,et al.  Neoadjuvant Docetaxel, Capecitabine and Cisplatin (DXP) in Patients with Unresectable Locally Advanced or Metastatic Gastric Cancer , 2010, Annals of Surgical Oncology.

[24]  M. Makuuchi,et al.  The Clavien-Dindo Classification of Surgical Complications: Five-Year Experience , 2009, Annals of surgery.

[25]  Masahiro Takeuchi,et al.  S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. , 2008, The Lancet. Oncology.

[26]  N. Demartines,et al.  Classification of Surgical Complications: A New Proposal With Evaluation in a Cohort of 6336 Patients and Results of a Survey , 2004, Annals of Surgery.

[27]  T. Takayama,et al.  Conversion therapy for inoperable advanced gastric cancer patients by docetaxel, cisplatin, and S-1 (DCS) chemotherapy: a multi-institutional retrospective study , 2016, Gastric Cancer.

[28]  K Nishikawa,et al.  Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  E. Oki,et al.  Clinical significance of adjuvant surgery following chemotherapy for patients with initially unresectable stage IV gastric cancer. , 2015, Anticancer research.

[30]  Japanese Gastric Cancer Association.  Japanese classification of gastric carcinoma: 3rd English edition , 2011, Gastric Cancer.